Zymeworks (Zymeworks) Momentum Rank : 10 (As of Apr. 28, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Zymeworks Momentum Rank?

Zymeworks has the Momentum Rank of 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of Zymeworks's Momentum Rank

For the Biotechnology subindustry, Zymeworks's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zymeworks's Momentum Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zymeworks's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Zymeworks's Momentum Rank falls into.

Zymeworks Momentum Rank Related Terms

Thank you for viewing the detailed overview of Zymeworks's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Zymeworks (Zymeworks) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zymeworks Inc (NAS:ZYME) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

ZA8:Germany

Address

108 Patriot Drive, Suite A, Middletown, DE, USA, 19709

Website

https://www.zymeworks.com

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Executives

Paul Andrew Moore	officer: Chief Scientific Officer	114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Christopher Astle	officer: SVP & Chief Financial Officer	114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Kenneth Galbraith	director, officer: Chair & CEO	OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1
Carlos Campoy	director	11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Miller Derek John Michael	director	108 PATRIOT DRIVE, SUITE A, 1385 WEST 8TH AVENUE, SUITE 540, MIDDLETOWN DE 19709
Neil A Klompas	officer: President & COO	114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Lota S. Zoth	director	334 CR 692, BUFFALO GAP TX 79508
Troy Cox	director	C/O FOUNDATION MEDICINE, INC., C/O FOUNDATION MEDICINE, INC., 150 SECON, CAMBRIDGE MA 02141
Kenneth J. Hillan	director	C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Hollings Renton	director
Kelvin Neu	director	860 WASHINGTON STREET, 10TH FLOOR, NEW YORK NY 10014
Natalie Sacks	director	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Susan Mahony	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Neil Josephson	officer: Chief Medical Officer	114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4